Navigation Links
Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
Date:1/26/2009

Novel Fluoroquinolone Demonstrates Safety and Efficacy in Treatment of Skin Infections

NEW HAVEN, Conn., Jan. 26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive final results from a Phase 2 clinical trial of its novel fluoroquinolone antibiotic, delafloxacin (RX-3341), in the treatment of complicated skin and skin structure infections (cSSSI).

Separately, Rib-X today also announced that the company closed on a $25 million financing, which will fund the ongoing development of its pipeline of novel antibiotics. This round included participation from all of Rib-X's major investors, including: Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, S.R. One, and Vox Equity Partners I.

In the double-blind study, delafloxacin was administered intravenously at two different doses, 300 mg twice daily (BID) and 450 mg BID; the comparator was tigecycline (TYGACIL(R), Wyeth Pharmaceuticals), the only broad spectrum agent recently approved (2005) by the FDA for use in cSSSI. Delafloxacin showed comparable efficacy and improved tolerability relative to tigecycline at the FDA-approved dosing regimen for this indication. In the clinically evaluable population, the cure rates for delafloxacin 300 mg BID and 450 mg BID were 97.2% and 92.5%, respectively, while the cure rate for tigecycline was 91.2%.

Staphylococcus aureus was the most frequently isolated pathogen, accounting for approximately 85% of all pathogens collected. Approximately 70% (68/96) of the S. aureus isolates were methicillin-resistant (MRSA) and 63% of the MRSA were levofloxacin resistant. MIC90 values for delafloxacin, tigecycline, and levofloxacin against all S. aureus'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
2. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
3. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
6. Axikin Pharmaceuticals Spins out of Actimis
7. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
8. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Cumberland Pharmaceuticals Appoints Lee Product Director
10. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
11. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... Ohio (PRWEB) July 10, 2014 Understanding ... ion channel-expressing cell lines, and the gap that currently ... cells that expand its industry-leading portfolio of validated ion ... on ion channel-expressing cell lines, as ion channels control ... to control this activity creates the potential to treat ...
(Date:7/10/2014)... San Francisco, CA (PRWEB) July 10, 2014 ... a family closer together. The Archer Family purchased ... information contained within DNA, but ended up with a ... surprising discoveries contained within the family members’ DNA genuinely ... family had decided to search deeper into genetic history ...
(Date:7/10/2014)... 2014 OMICS Group’s 5th International conference ... August, 2014 at Double Tree by Hilton Beijing, China ... in Analytical & Bioanalytical research methods only to facilitate ... this occasion, Dr. Srinubabu Gedela, MD of OMICS Group ... a remarkable one in bringing a unique and international ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... GeneGo, Inc., the leading systems biology tools company, ... curated pathway maps from GeneGo, Inc. for their ... www.millipore.com/pathways , the tool links Millipore,s cutting edge ... bioinformatics content to related biological pathways. These maps ...
... company Pharmaxis,(ASX: PXS; Nasdaq: PXSL ) today ... senior management team in the position of Chief Medical ... pharmacovigilance and,medical affairs. Clinical Operations will continue to ... Dr Fox has more than 15 ...
... Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical ... an agreement with Advanced Vision Research, Inc. (AVR) ... AVR,s new MacuTrition(R) oral retinal nutritional supplement and ... gland therapy. AVR is a privately held ophthalmic ...
Cached Biology Technology:Millipore Launches an Interactive Biological Pathway Tool Using GeneGo's Manually Curated Pathway Maps 2Millipore Launches an Interactive Biological Pathway Tool Using GeneGo's Manually Curated Pathway Maps 3Pharmaxis Builds Senior Management Team 2Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health 2Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health 3
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... Social animals often develop relationships with other group members ... In wild chacma baboons the strategy for grooming activities ... are just published in the scientific journal Biology ... of baboons is not practiced without ulterior motives. To ... for the individual, while grooming another individual can provide ...
(Date:7/11/2014)... of mesenchymal stem cells can stimulate neurogenesis in the ... disease (AD) and improve tissue and function injury under ... on the therapeutic effect of adipose-derived stem cells (ADSCs) ... on oxidative injury and neurogenesis in the brain of ... of Life Sciences, Tsinghua University, China transplanted ADSCs into ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... of scientists at the Instituto Gulbenkian de Cincia, in Portugal, ... organ size. The team, led by Florence Janody, show in ... that regulates the skeleton of the cell also acts to ... Their findings have implications for cancer research, as they add ...
... athletes who have stopped menstruating have a weakening in the ... breaking a bone, despite getting plenty of weight-bearing exercise, a ... The Endocrine Society,s 93rd Annual Meeting in Boston. "Given ... athletic activities and the fact that up to 24% of ...
... COLUMBIA, Mo. A new University of Missouri study ... (BPA) through diet has been underestimated by previous lab tests. ... were given a steady diet supplemented with BPA throughout the ... exposure, and found an increased absorption and accumulation of BPA ...
Cached Biology News:Scientists uncover role for cell scaffold in tumor formation 2Athletic girls more likely to have impaired bone structure if menstrual cycle stops 2Exposure to BPA has been underestimated, new MU research says 2
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Agarose II (Low Melt)...
...
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
Biology Products: